Eleusis evaluates potential of LSD in treating Alzheimer’s Disease
Category: #health  By Mateen Dalal  Date: 2019-12-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eleusis evaluates potential of LSD in treating Alzheimer’s Disease

A clinal stage life science company, Eleusis recently announced results from the Phase 1 clinical trial of LSD (Lysergic Acid Diethylamide), demonstrating the potential of the orally administered low doses of the drug for the treatment of Alzheimer’s disease.

The study demonstrates positive data on the pharmacokinetics, pharmacodynamics, tolerability and safety in healthy-older volunteers over a period of 3 weeks. In the past, LSD has shown clinically relevant therapeutic effects in patients afflicted by substance abuse, depression and anxiety. Prior research also suggests that a low dose LSD may have considerable potential in treating Alzheimer’s disease. This trial conducted by Eleusis was the first registered modern clinical trial on low doses of LSD.

Neiloufar Family, Director of Research at Eleusis and the lead investigator in the study was reportedly quoted saying that they are encouraged by the study results as it provides reassuring safety data and that the frequency of adverse events associated with Lysergic Acid Diethylamide is similar to placebo.

Charles Nichols, Professor of Pharmacology at Louisiana State University and co-author of the study was reported to state that this research with serotonin receptor agonists like LSD, represent a new strategy to treat diseases associated with chronic inflammation.

The unique polypharmacology of LSD may serve to enhance its capacity to regulate several key pathological processes in the brain that are associated with Alzheimer’s disease, along with the neuroinflammation, that are implicated in its progression from mild cognitive impairment.

Shlomi Raz, Chairman & Founder, Eleusis. Stated that the company is exhilarated to share the results of the groundbreaking trial of LSD and consider that this study will serve as the foundation for the promising therapeutic development of Lysergic Acid Diethylamide drug and other psychedelic drugs as therapeutics. Raz added that they are looking forward to unravelling the therapeutic potential of psychedelics at non-psychoactive, subperceptual, doses, to safely address the most urgent unmet needs in public health.

Source Credit: https://www.eleusisltd.com/news/2019/12/18/eleusis-announces-phase-1-trial-results-of-lysergic-acid-diethylamide-lsd-in-healthy-older-volunteers-potential-to-evaluate-as-disease-modifying-therapy-for-alzheimers-disease

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...